Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ACTUATE THERAPEUTICS, INC. (ACTU)

Actuate Therapeutics closes $9.96 million net share and warrant offering priced at $0.71

Negative Impact 3 of 5 financing Written later

Actuate Therapeutics closed an underwritten public offering on October 28, 2026, selling 30,985,900 shares of common stock and warrants for up to 15,492,950 shares, with Newbridge Securities Corporation as sole book-running manager. Net proceeds were approximately $9.96 million, which the company intends to use for working capital and general corporate purposes. The new shares and warrants increase the number of shares outstanding and could dilute existing shareholders.

Key points

  • Offering priced at $0.71 per set of two shares and one Common Warrant, before underwriting discounts and commissions
  • Common Warrants exercisable at $0.45 per share, immediately upon issuance, expiring five years after issuance
  • Net proceeds of approximately $9.96 million; the press release had projected gross proceeds of $11.0 million
  • Underwriter has a 45-day option to buy up to 4,647,885 additional shares and 2,323,942 additional warrant shares

The filing

CompanyACTUATE THERAPEUTICS, INC. (ACTU)
Form8-K, current report
Filed with the SECOct 28, 2026, 5:17 PM ET
Accession number0001683168-26-008143

Items reported: 1.01 Material Definitive Agreement8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.